Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Just Hit the Watchlist: See Why Market Crux is Highlighting
(NYSE: MAIA) This Morning—Wednesday, April 29, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.
We Have All Eyes On (MAIA) This Morning
Get (MAIA) On Your Radar While It’s Still Early… April 29, 2026
Market Crux | (MAIA) Just Triggered Multiple Bullish Signals—Check It Out Now
Dear Reader, Market Crux has (MAIA) pulled up right now — and TradingView’s technical analysis dashboard is showing multiple bullish signals.
Behind the ticker is MAIA Biotechnology, Inc., a company pursuing ateganosine (THIO), designed to disrupt cancer cell replication while supporting immune activation. That’s why (MAIA) is leading the Market Crux watchlist this morning—Wednesday, April 29, 2026. Keep in mind, two firms currently cover (MAIA) with bullish targets.
Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, carries an Outperform rating and a $14.00 target — suggesting over 1,000% upside potential from the recent $1.24 range.Hunter Diamond, CFA at Diamond Equity Research, recently updated his valuation to $10.27 per share, which suggests over 700% upside potential from current levels, after raising his probability of clinical success from 25% to 35% to reflect the Phase 3 initiation and FDA Fast Track designation momentum. With two active clinical trials running simultaneously, fresh survival data turning heads at an international lung cancer congress, and analysts assigning targets that represent four-figure percentage upside potential from recent levels, (MAIA) has our full attention. Company Overview
Founded in 2018 and headquartered in Chicago, Illinois, MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company focused on targeted therapy and immuno-oncology. Its corporate mission is to meaningfully improve and extend the lives of people with cancer through novel, first-in-class mechanisms of action. The centerpiece of (MAIA)'s pipeline is ateganosine — also known as THIO or 6-thio-2'-deoxyguanosine — a purine nucleoside analog that exploits the telomerase enzyme present in over 80% of human cancers. 
Telomerase, absent in healthy somatic cells but active in the vast majority of malignancies, is what allows cancer cells to divide indefinitely. Ateganosine hijacks that very mechanism — it is incorporated into cancer cell telomeres via telomerase, then compromises the telomeric structure, triggering rapid tumor cell death. Beyond direct telomere destruction, THIO also generates an immunogenic effect — converting immunologically "cold" tumors into "hot" tumors responsive to checkpoint inhibitors. (MAIA)'s primary focus is non-small cell lung cancer (NSCLC), a disease affecting over 2.2M patients annually worldwide. The company has two active NSCLC trials: the ongoing Phase 2 THIO-101 study evaluating ateganosine sequentially with Libtayo® (cemiplimab, from Regeneron), and the pivotal Phase 3 THIO-104 trial comparing ateganosine plus Libtayo® against investigator's choice of chemotherapy in third-line NSCLC patients resistant to both checkpoint inhibitors and platinum-based therapy.
A $50B+ Market With No Standard of Care
for Third-Line NSCLC
The global checkpoint inhibitor market generated approximately $50B in combined 2024 sales, with NSCLC representing more than 30% of total checkpoint inhibitor revenue. Yet for roughly 50,000 advanced NSCLC patients per year in the U.S. who have failed both immunotherapy and chemotherapy, there is currently no established standard of care — a critical unmet medical need with limited competitive pressure in the clinical trial setting. Survival Data That Stops You in Your Tracks
The efficacy signals emerging from THIO-101 are what separate MAIA from the crowd of clinical-stage oncology names. At the European Lung Cancer Congress 2026 (ELCC) in Copenhagen, MAIA presented data showing eight patients with relapsed or refractory NSCLC surviving beyond two years with no additional therapy after completing the trial. Four of those receiving second-line therapy survived over 30 months — compared with a published benchmark of 10.5 months for chemotherapy or checkpoint inhibitor monotherapy. One third-line patient survived 33 months, against an expected survival of just 5.8 months. Five of the eight remain alive with continued follow-up. The median overall survival in the third-line cohort stands at 17.8 months — roughly 3x the standard of care — with an 88% disease control rate and a 38% overall response rate (4-6x standard of care benchmarks). Funded, Advancing, and Phase 3 Enrolling
In March 2026, MAIA completed a $30M underwritten public offering, issuing 20M shares at $1.50 each with participation from healthcare-dedicated institutions— and notably, no warrant coverage. Subsequently, a $33M capital raise is expected to fully fund the ongoing Phase 3 THIO-104 trial through its key efficacy analyses. A U.S. site was activated in April 2026 for the Phase 2 international expansion. Using Bayesian statistical modeling on Phase 2 3L survival data, MAIA has calculated a 96% probability of technical success at the Phase 3 interim analysis, and 99% at the final analysis. The company also holds an FDA Fast Track Designation for third-line NSCLC, plus three FDA Orphan Designations covering hepatocellular carcinoma, small cell lung cancer, and malignant gliomas. 
Clinical supply agreements with Regeneron (cemiplimab), BeOne Medicines (tislelizumab), and Roche (atezolizumab) signal meaningful validation from major pharmaceutical partners. Why (MAIA) Is Sitting at the Top of Our Morning Watchlist
Right Now—Wednesday, April 29, 2026…
1. No Competition: Roughly 50,000 advanced NSCLC patients per year in the U.S. have no established standard of care after failing both immunotherapy and chemotherapy, representing the exact population (MAIA) is targeting in its pivotal Phase 3 trial.
2. Analyst Targets: Robert LeBoyer at Noble Capital Markets has a $14 target on (MAIA), which suggests over 1,000% upside potential from the recent $1.24 range. 3. FDA Fast Track: The FDA has granted (MAIA) a Fast Track Designation for third-line NSCLC, a regulatory status that enables more frequent communication with the FDA and eligibility for accelerated approval — potentially shortening the timeline to commercialization. 4. 99% Success Odds: Using Bayesian statistical modeling on real Phase 2 patient data, (MAIA) has calculated a 96% probability of technical success at the Phase 3 interim analysis and 99% at the final analysis. 5. Fully Funded: A recent $33M capital raise is expected to fully cover (MAIA)'s pivotal Phase 3 trial through its key efficacy analyses, removing near-term financing uncertainty at a critical clinical moment. 6. Survival Milestone: Eight patients in (MAIA)'s THIO-101 trial survived beyond two years with no additional therapy after completing the trial — against an expected survival benchmark of just 5.8 months for third-line patients. 7. Big Pharma Validated: Clinical supply agreements with Regeneron, BeOne Medicines, and Roche signal that three major pharmaceutical partners have formally committed to supporting (MAIA)'s ongoing and planned clinical trials. Get (MAIA) On Your Radar While It’s Still Early…
(MAIA) is lighting up our radar right now. (MAIA) is backed by multiple global pharmaceutical companies supporting its clinical programs, holds an FDA Fast Track designation that may help accelerate regulatory interaction, and is advancing a pivotal Phase 3 trial in a patient population where treatment options remain limited. Early clinical results have already shown extended survival in certain cases well beyond typical expectations, while internal modeling based on prior data suggests a high probability of technical success as the trial progresses. Take a look at (MAIA) while it’s still early. We have all eyes on (MAIA) this morning—Wednesday, April 29, 2026. Keep an eye out for my next update, it could be here very shortly. Sincerely, Gary Silver
Managing Editor,
MarketCrux
|
Visit our YouTube Channel - Eagle Investing Network
